In this exclusive interview, CEO of NewAmsterdam Pharma, Michael Davidson, offers insight into the low-density lipoprotein (LDL) cholesterol lowering therapeutic landscape and shares promising data from the company’s lead candidate, a cholesterol ester transfer protein (CETP) inhibitor.
Dr Michael Davidson is CEO of biotech company NewAmsterdam Pharma. He is a cardiologist, lipidologist and professor and director of the LIP clinic at University of Chicago in the US. In this Q&A, he explores the trends and challenges within the cardiovascular treatment space, as well as clinical development of the company’s lead candidate obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor for lowering low-density lipoprotein-cholesterol (LDL-C) and ultimately reducing cardiovascular risk.
“For at least a decade from 2013 until recently, LDL lowering treatments were stuck on a paradigm of just putting people on statins and not getting LDL levels down to certain goals”
CETP inhibitors have been around for a while, but they have unfortunately been unsuccessful in getting onto the market commercially. Although not caused by the target itself, there have been four failures in the past, Dr Davidson explained.
For at least a decade from 2013 until recently, LDL lowering treatments were stuck on a paradigm of just putting people on statins and not getting LDL levels down to certain goals, he added.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Dr Davidson highlighted that while heart disease rates have dropped over the last two decades, they have started to rise again.
There are “many reasons” he shared. “Obesity, metabolic syndrome, diabetes epidemic is global, so that aggravates cardiovascular risk… we are seeing a marked acceleration of heart disease deaths, and we need to find new therapies to make a difference. We are hopeful that NewAmsterdam Pharma is part of that solution with obicetrapib.”
What are the top three trends impacting the cardiovascular drug development space today?
Even though patients are on existing [statins] that are well-documented and most likely safe and effective, there are many patients who still have cardiovascular disease, the leading cause of death”
We are recognising now is that there is great data on how to reduce risk by applying lipid lowering therapy like statins. However, there is still what is called a residual risk. Even though patients are on these existing therapies that are well-documented and most likely safe and effective, there are many patients who still have cardiovascular disease, the leading cause of death.
That residual risk falls into three different categories. The first is obesity, which is being addressed by GLP-1 therapies. These treatments have become very much part of the mainstream of how we reduce cardiovascular risk. Obicetrapib has a tremendous potential benefit in reducing lipid residual risk. The third part of residual risk is inflammation, and new drugs are being focused on reducing inflammation to address this risk.
Can you give a brief overview of obicetrapib and its potential for reducing LDL cholesterol?
As a CETP inhibitor, obicetrapib has been developed specifically to lower LDL cholesterol.
In our Phase II trials, obicetrapib has shown a reduction [of LDL cholesterol] in the range of 40 to 51 percent”
This target is very effective and has the potential to reduce LDL and cardiovascular risk. In our Phase II trials, obicetrapib showed a reduction in the range of 40 to 51 percent.
NewAmsterdam Pharma is moving forward into our Phase III trials in the high LDL populations and ultimately, we want to show the benefit of obicetrapib on reducing cardiovascular events.
How do CETP inhibitors work in lowering LDL cholesterol?
CETP is a transfer protein that moves cholesterol from HDL into LDL. When you block it, HDL cholesterol goes up and LDL cholesterol goes down. However, more importantly, that transfer inhibition results in more uptake of cholesterol by the liver and more removal of cholesterol by the intestines. Overall, this leads to more cholesterol being removed from the body. This has ultimately been associated with cardiovascular events and many other ways of lowering LDL cholesterol, to reduce risk in patients at risk for heart disease.
Can you elaborate on some of the results from NewAmsterdam Pharma’s recent clinical trials for lowering cardiovascular risk?
In our Phase II programme, we wanted to focus on patients already on statins who had LDL levels that were still too high, with high cardiovascular risk.
a fixed dose combination of obicetrapib and ezetimibe… [as] a single pill could be one of the most effective LDL lowering therapies, especially as an oral therapy to reduce cardiovascular risk”
In the Phase II ROSE trial, all the participants were on high intensity statins, which is defined as 40 or 80mg of atorvastatin, generic Lipitor or 20 or 40mg of Rosuvastatin, generic Crestor (rosuvastatin). Then we added obicetrapib to those patients; and this showed a 51 percent median reduction.
We also showed that in combining obicetrapib with ezetimibe, we got 63 percent LDL lowering. So we are proceeding with developing a fixed dose combination of obicetrapib and ezetimibe, which would be a single pill that could be one of the most effective LDL lowering therapies, especially as an oral therapy to reduce cardiovascular risk.
What are the benefits for patients taking fixed dose combinations in one pill to reduce LDL cholesterol?
Most importantly, it provides greater efficacy. Obicetrapib alone is in the 40 percent range. Ezetimibe traditionally is in the 15 to 20 percent range. If you put the two together, you actually get synergy more than expected. That is what we showed in our ROSE II trial. Almost all participants achieved the goal using this combination regime.
Entresto (sacubitril/valsartan) is an example of two drugs together having synergy. We believe the same is true for obicetrapib and ezetimibe, not just for LDL lowering but also for reducing atherosclerosis. NewAmsterdam Pharma is exploring the science behind using a combination of two drugs to further reduce atherosclerotic progression. That is one of the key science insights that we learned from our ROSE II trial.
What approaches is NewAmsterdam Pharma focusing on in relation to patient enrolment?
It all comes down to having good site selection, working with a good CRO partner, having academic leadership on the trial, then continuing to work with the sites to maximise their enthusiasm for the trial. It is essential to present what is new and exciting about the therapy.
But most importantly, it is continued site engagement. Since participation is voluntary for patients, we do have to aspire to keep them motivated and engaged in the study, especially for the long-term outcome study, which goes on for five years or so.
Beyond clinical trials, what other challenges are impacting pharmaceutical companies today?
Currently, biotech is predominantly focused on oncology, gene therapy and rare diseases. You see very few cardiovascular companies as a startup biotech, and there are reasons for that. It takes a lot of capital. Large trials take time to get to the finish line.
While Pharma has focused a lot on oncology successfully with many new therapies, there is a trend now to refocus back on cardiovascular.
I do think we are going to start seeing LDL lowering treatments get back on track. But we also have some other exciting therapies like lipoprotein LPL(a) lowering treatments that are on the horizon that addresses residual risk.
In 2024, what milestones does NewAmsterdam Pharma hope to reach?
First, we have the readout from our BROOKLYN Phase III trial, evaluating patients with familial hypercholesterolemia (HeFH) on maximum tolerated statins. In this autosomal dominant genetic disorder, LDL levels are still too high, which comes with very high risk of heart disease. This is our first major Phase III trial read out, which will come in the third quarter of 2024.
Then the second trial is called BROADWAY evaluating approximately 2,500 patients. The patients are on maximum tolerated statins and they have predominantly atherosclerotic cardiovascular disease (ASCVD). That will be our pivotal trial for not just LDL lowering, but also for safety in Phase III, because it is a very large trial. The readout for this trial will come out in the fourth quarter of 2024.
About the interviewee
Dr Michael Davidson joined NewAmsterdam Pharma as CEO and Executive Board member as of August 2020. Before joining NewAmsterdam Pharma, Michael was founder and Chief Medical Officer of Corvidia Therapeutics, which was sold to Novo Nordisk in July 2020. Michael was the cofounding Chief Medical Officer of Omthera Pharmaceuticals in 2008. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the US and was acquired by Pharmaceutical Product Development in 1996.
His research background encompasses pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Michael served as President of the National Lipid Association from 2010 to 2011. He received his BA and MS from Northwestern University and his MD from The Ohio State University College of Medicine.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.